VRX - Valeant Pharmaceuticals International, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
    PR Newswire

    Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference

    Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.

  • Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
    CNW Group

    Bausch Health Announces 2020 Annual Meeting Of Shareholder Results

    Bausch Health Announces 2020 Annual Meeting Of Shareholder Results

  • Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
    CNW Group

    Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes

    LAVAL, Quebec , Feb. 19, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order to extend and reprice its existing term loan facility and revolving credit facility and make certain other amendments to the terms of the facilities in connection therewith (collectively, the "Credit Agreement Refinancing"). Additionally, the Company intends, subject to market conditions, to have Bausch Health Americas, Inc. ("BHA"), a wholly-owned indirect subsidiary of the Company, issue $3.25 billion of secured debt securities (the "New Debt Securities").

  • Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
    CNW Group

    Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program

    LAVAL, Quebec , Feb. 3, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a $10,000 scholarship in support of their academic goals.

  • Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
    CNW Group

    Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients

    LAVAL, Quebec , Oct. 10, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the 2019 Aspire Higher scholarship program recipients. The program, which since 2013 has granted more than $648,000 in scholarships to students who have been affected by dermatologic conditions, will award nine students with scholarships of $10,000 each to pursue their undergraduate or graduate degrees.